MBOAT2 and cancer: These insights establish TLKs as pharmacologically exploitable targets in ALT-driven tumors and chromosomally unstable cancers, while providing mechanistic context for understanding how the circ-MBOAT2 coordinates immune evasion in NSCLC pathogenesis through TLK1-dependent regulation [40].